Drug Taken for Common Condition May Be Slowing Alzheimer’s Decline

A blood-thinning medication commonly used to treat irregular heartbeats may also help slow cognitive decline in patients with Alzheimer’s disease, according to new research from Karolinska Institutet in Sweden. Published in the European Heart Journal, the study suggests that newer anticoagulants, known as NOACs, are associated with a slower rate of cognitive deterioration in individuals who suffer from both atrial fibrillation and Alzheimer’s. The research analyzed data from SveDem, Sweden’s national quality register for cognitive disorders and dementia, focusing on 7,308 individuals diagnosed with both conditions. Participants were divided into three groups: those receiving NOACs, those on warfarin, and those with no anticoagulant therapy. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), a widely accepted tool for evaluating memory and reasoning abilities. Over time, the study observed that patients on NOACs experienced a slower decline in cognitive function, with a reduction of approximately 0.2 MMSE points annually compared to those on warfarin or no treatment. In addition to cognitive benefits, the study noted that NOACs were linked to a reduced risk of several adverse outcomes, including death, stroke, blood clots, and fractures. While warfarin also showed some protective effects against these complications, it carried a higher risk of severe bleeding compared to NOACs. These findings suggest that NOACs may offer a safer and more effective alternative for managing both atrial fibrillation and its potential impact on cognitive health in Alzheimer’s patients. Atrial fibrillation, a common heart condition affecting older adults, is frequently observed alongside Alzheimer’s disease. Doctors typically prescribe anticoagulants to prevent dangerous blood clots in patients with this rhythm disorder. Previous studies had hinted that such treatments might lower the overall risk of dementia, but little was known about their role in slowing cognitive decline in those who already have Alzheimer’s. This latest research provides insight into how specific types of anticoagulants might influence cognitive outcomes in this vulnerable population. Maria Eriksdotter, a professor at Karolinska Institutet and lead researcher of the study, explained that the observed effects may stem from improved cerebral circulation and reduced microvascular damage. “There are reasons to believe that the treatment could have a positive effect on cognition,” she stated. However, the study’s design, as an observational analysis, means that direct causation cannot be established. Researchers acknowledged that other variables, such as differences in patient characteristics or treatment adherence, could have influenced the results. Dr. Mohammad Bakhtiar, a general practitioner based in England, commented on the significance of the findings. He emphasized that the large sample size, over 7,000 participants, makes the results more credible than smaller clinical trials. “The cognitive difference is modest, but it sits alongside fewer strokes, clots and deaths, and less major bleeding than warfarin,” he noted. For healthcare providers, the study offers valuable guidance in choosing between NOACs and warfarin for patients with both conditions. Despite the promising results, the researchers caution that further studies are needed to confirm the causal relationship between NOAC use and slowed cognitive decline. They highlighted that patients on NOACs may differ from those on no treatment in terms of health status, support systems, or access to specialized care. Additionally, some participants changed medications during the study period, complicating the interpretation of long-term outcomes. As such, the findings represent an association rather than definitive proof.